Can acupuncture boost brain function in Alzheimer's? new trial aims to find out
NCT ID NCT03810794
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding acupuncture to the standard Alzheimer's drug donepezil can improve memory, daily living skills, and quality of life. Researchers will compare two groups of 90 patients each: one gets acupuncture plus donepezil, the other gets donepezil alone. The trial involves 36 acupuncture sessions over 12 weeks and will measure changes in thinking tests and daily function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- acupuncture
- What this could lead to
- If it works, this could point toward a safe, drug-free add-on therapy to help people with Alzheimer's maintain thinking skills and daily function longer.
- What could go wrong
- This is a mid-sized, early-stage trial with no blinding of patients, so results may be influenced by placebo effects. Acupuncture is generally safe but may cause minor bruising or discomfort.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2019
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * aged between 50-85 years * the diagnostic criteria of Neurological Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) * cognitive impairment based on the scores of the Chinese version of the Mini Mental State Examination (MMSE) (patients with mild to moderate Alzheimers disease, 11≤primary school degree≤22, 11≤junior high school degree or above≤26 * magnetic resonance imaging (MRI) confirmation of atrophy of the hippocampus or the medial temporal lobe volume, MRI manifestation of high possibility of Alzheimer Disease * the Medial Temporal Lobe Atrophy Rating Scale (MTA-scale) score (≥2 for those under 75 years, and ≥3 for those over 75 years) * voluntarily joining this study with informed consents Exclusion Criteria: * cognitive impairment caused by other factors (e.g. vascular dementia, dementia with Lewy bodies, frontotemporal dementia, hormone or metabolic abnormalities, hypothyroidism, folic acid or vitamin B12 deficiency, delirium or other mental and emotional disorders (such as schizophrenia and depression)) * a serious heart condition, hepatic disease, renal system disease, hematopoietic system disease, or whole-body malnutrition * aphasia, disturbance of consciousness, or failure to cooperate with the related examinations due to physical disability * anticoagulant treatments such as warfarin or heparin * use of pacemakers or receiving acupuncture in the past 2 weeks
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Huashan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200040, China
-
LongHua Hospital Shanghai University of Traditional Chinese Medicine
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Shanghai Mental Center, Shanghai Jiaotong University of Medicial School
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Can heart rehab and brain training sharpen thinking?
- Can group singing and rhythm help Long-Term care residents with cognitive impairment?
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades